Literature DB >> 1553167

Factors influencing serum CA 125 levels in normal women.

S Grover1, M A Quinn, P Weideman, H Koh.   

Abstract

Serum CA 125 levels were studied in 2544 healthy women. Menopausal status and a history of hysterectomy were both highly significant influences on the CA 125 level (P less than .0001 for both factors). A history of hormone replacement therapy was also highly significant in reducing CA 125 levels (P = .002) in postmenopausal women. Other factors such as parity, history of unilateral oophorectomy or oral contraceptive usage, or family history of ovarian cancer were not significant influences when analysis of covariance was performed. When premenopausal women were assessed separately, age was significant (P = .04). The number of years since menopause did not influence CA 125 levels. Both hysterectomy and menopausal status have a clear effect on serum CA 125 levels and must be considered if serum CA 125 is to be used as a screening test.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1553167

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  9 in total

1.  The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.

Authors:  Christine C Johnson; Bruce Kessel; Thomas L Riley; Lawrence R Ragard; Craig R Williams; Jian-Lun Xu; Saundra S Buys
Journal:  Gynecol Oncol       Date:  2008-06-30       Impact factor: 5.482

2.  Does HE4 have a role as biomarker in the recurrence of ovarian cancer?

Authors:  Francesco Plotti; Stella Capriglione; Corrado Terranova; Roberto Montera; Alessia Aloisi; Patrizio Damiani; Ludovico Muzii; Giuseppe Scaletta; Pierluigi Benedetti-Panici; Roberto Angioli
Journal:  Tumour Biol       Date:  2012-08-09

3.  Chronic Medical Conditions and CA125 Levels among Women without Ovarian Cancer.

Authors:  Babatunde O Akinwunmi; Ana Babic; Allison F Vitonis; Daniel W Cramer; Linda Titus; Shelley S Tworoger; Kathryn L Terry
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-09-20       Impact factor: 4.254

4.  Involvement of ovarian factors magnified by pharmacological induction of multiple follicular development (MFD) in the increase in Ca125 occurring during the luteal phase and the first 12 weeks of induced pregnancies.

Authors:  A M Paoletti; G G Serra; V Mais; S Ajossa; S Guerriero; M Orrù; G B Melis
Journal:  J Assist Reprod Genet       Date:  1995-04       Impact factor: 3.412

5.  Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.

Authors:  Steven J Skates; Phuong Mai; Nora K Horick; Marion Piedmonte; Charles W Drescher; Claudine Isaacs; Deborah K Armstrong; Saundra S Buys; Gustavo C Rodriguez; Ira R Horowitz; Andrew Berchuck; Mary B Daly; Susan Domchek; David E Cohn; Linda Van Le; John O Schorge; William Newland; Susan A Davidson; Mack Barnes; Wendy Brewster; Masoud Azodi; Stacy Nerenstone; Noah D Kauff; Carol J Fabian; Patrick M Sluss; Susan G Nayfield; Carol H Kasten; Dianne M Finkelstein; Mark H Greene; Karen Lu
Journal:  Cancer Prev Res (Phila)       Date:  2011-09

6.  Factors influencing serum concentration of CA125 and CA15-3 in Iranian healthy postmenopausal women.

Authors:  Alamtaj Samsami Dehaghani; Alireza Fotouhi Ghiam; Marjan Hosseini; Sareh Mansouri; Abbas Ghaderi
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

7.  The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.

Authors:  Mani Nassir; Jun Guan; Hrvoje Luketina; Timo Siepmann; Irena Rohr; Rolf Richter; Dan Cacsire Castillo-Tong; Robert Zeillinger; Ignace Vergote; Els Van Nieuwenhuysen; Nicole Concin; Christian Marth; Christina Hall; Sven Mahner; Linn Woelber; Jalid Sehouli; Elena Ioana Braicu
Journal:  Tumour Biol       Date:  2015-09-29

8.  Reliability of tumor markers, chemokines, and metastasis-related molecules in serum.

Authors:  Faina Linkov; Yian Gu; Alan A Arslan; Mengling Liu; Roy E Shore; Lyudmila Velikokhatnaya; Karen L Koenig; Paolo Toniolo; Adele Marrangoni; Zoya Yurkovetsky; Anne Zeleniuch-Jacquotte; Anna E Lokshin
Journal:  Eur Cytokine Netw       Date:  2009-03       Impact factor: 2.737

9.  [A retrospective study of ovarian cancer with a median follow of 42 months].

Authors:  Fanomezantsoa Raherinantenaina; Solonirina Davidà Rakotomena; Nomeharisoa Rodrigue Emile Hasiniatsy; Felantsoa Auberlin Rakototiana; Florine Rafaramino; Hery Nirina Rakoto Ratsimba
Journal:  Pan Afr Med J       Date:  2015-03-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.